Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer

DISEASE CHARACTERISTICS:

• Histologically or cytologically proven diagnosis of a malignant disease for which no satisfactory treatment exists at the time of enrollment
• Patients with brain metastases that, at the time of study enrollment, are controlled and do not require treatment with corticosteroids are eligible

PATIENT CHARACTERISTICS:

• WHO performance status 0-2
• Life expectancy ≥ 3 months
• ANC > 1.5 x 10^9/L
• Platelet count > 100 x 10^9/L
• Creatinine clearance > 50 mL/min
• Serum bilirubin < 1.5 mg/dL
• AST or ALT < 2.0 times upper limit of normal (unless clearly due to the presence of tumor)
• Not pregnant or nursing
• Fertile patients must use effective contraception
• Patient must be capable of understanding the nature of the trial and must give written informed consent
• No unstable or severe intercurrent medical conditions or active, uncontrolled infection
• No history of allergic reactions to nonsteroidal anti-inflammatory drugs
• No bleeding peptic ulcer within the past 3 months
• No allergy to sulfa drugs

PRIOR CONCURRENT THERAPY:

• Recovered from all prior therapy
• No radiotherapy or chemotherapy within the 3 weeks (nitrosoureas or mitomycin C within 6 weeks) prior to anticipated first day of dosing
• No concurrent therapy with other investigational agents or antineoplastic therapy